Notice Number: NOT-HL-16-304
Release Date: February 22, 2016
Estimated Publication Date of Announcement: April 2016
First Estimated Application Due Date: October 2016
Earliest Estimated Award Date: Summer 2017
Earliest Estimated Start Date: Summer 2017
National Heart, Lung, and Blood Institute (NHLBI)
A number of NHLBI’s large, multi-site trials are solicited through PAR-13-128 Investigator-Initiated Multi-Site Clinical Trials (Collaborative R01). The upcoming expiration of PAR-13-128 presents an opportunity for NHLBI to implement new approaches to enhance the likelihood of clinical trial success and continue to support high-impact clinical trials that shape clinical practice and lead to improved health.
The purpose of this Notice is to inform potential applicants that the NHLBI intends to publish a Funding Opportunity Announcement (FOA) that will support a Data Coordinating Center for investigator-initiated multi-site clinical trials (Phase II and above) through a milestone-driven cooperative agreement (U24) award. A companion FOA is expected to be published in parallel for collaborative Investigator-Initiated Multi-site Clinical Trials: Clinical Coordinating Center (UG3/UH3) applications (see NOT-HL-16-303).
The FOA is expected to be published in Spring 2016 with an expected application due date in Fall 2016.
Details regarding the Data Coordinating Center FOA are being provided to allow potential applicants sufficient time to develop responsive projects and meaningful collaborations and to begin to consider the requirements that are part of the new milestone-driven award.
The key aspects of this new approach include:
The NHLBI encourages applicants to consider the following requirements of the new Data Coordinating Center FOA:
The Data Coordinating Center application should include the following elements:
NHLBI Program Staff will conduct a webinar in Spring/Summer of 2016 to answer questions from potential applicants about the new FOA and submission process.
APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.
Please direct all inquiries to:
Keary A. Cope, PhD
National Heart, Lung and Blood Institute (NHLBI)